Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival
among women with Stage 1 endometrial cancer: a randomized clinical trial.
The combination of a single HDR treatment and a short course of EBRT can result in a biochemical disease-free survival
of over 95% (Table 2), with a low rate of late toxicity.
The authors note that these results suggest that breast cancer patients, such as those in this study, do not benefit from the addition of ALND in terms of local control, disease-free survival
, or overall survival, and that ALND may no longer be justified for certain patients.
Key Findings: For the most part, blinded trials studying patients with gastric, esophageal, lung, and colorectal cancer have reported significant improvements in survival and/or disease-free survival
The aim of this study was to determine the effect of Hb level at the start of treatment and mid-treatment on the response to treatment, local control, and pelvic disease-free and overall disease-free survival
Compared with standard therapy (paclitaxel every 3 weeks), paclitaxel weekly, docetaxel every 3 weeks, and docetaxel weekly increased the odds of disease-free survival
by 27%, 23%, and 9%, respectively, lead author Dr.
Outcome measures were all-cause and cancer mortality, disease-free survival
, cancer recurrence, second primary cancer, recurrence of a preinvasive lesion or progression to cancer.
The drug increased overall survival, disease-free survival
and quality of life for women where cancerous cells had spread to the lymph nodes, a spokesman said.
In particular, the agent helps reduce the risk of recurrence and achieve a prolonged disease-free survival
Researchers studied the effect of breast radiation in addition to tamoxifen on breast cancer relapse and disease-free survival
in 769 women age 50 or older with early-stage breast cancer.
In October, a study of 5,187 postmenopausal women by the National Cancer Institute of Canada found that Letrozole, an aromatase inhibitor, prolonged disease-free survival
by 43 percent.
For 4 years, that panel has lent its considerable influence to the early, aggressive use of antiretroviral therapy in patients who have relatively high CD4 T cell counts, even as evidence supporting the long-term clinical benefit of that practice has remained lacking, and even as observational data have shown that early therapy offers no disease-free survival